PainReform (PainReform) Debt-to-Revenue : N/A (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is PainReform Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

PainReform's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.06 Mil. PainReform's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.02 Mil. PainReform's annualized Revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

PainReform Debt-to-Revenue Historical Data

The historical data trend for PainReform's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PainReform Debt-to-Revenue Chart

PainReform Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

PainReform Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of PainReform's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, PainReform's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PainReform's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PainReform's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where PainReform's Debt-to-Revenue falls into.

PainReform Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

PainReform's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.056	+	0.03)	/	N/A
	=	N/A

PainReform's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.057	+	0.015)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

PainReform Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of PainReform's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

PainReform (PainReform) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PainReform Ltd (NAS:PRFX) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Yigal Alon Street, Tel Aviv, ISR, 6744316

Website

https://www.painreform.com

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.